Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
Top Cited Papers
Open Access
- 8 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 27 (11), 3196-3207
- https://doi.org/10.1038/s41418-020-0572-6
Abstract
SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease. The pathogenesis of severe cases remains unknown. We performed an in-depth prospective analysis of immune and inflammation markers in two patients with severe COVID-19 disease from presentation to convalescence. Peripheral blood from 18 SARS-CoV-2-infected patients, 9 with severe and 9 with mild COVID-19 disease, was obtained at admission and analyzed for T-cell activation profile, myeloid-derived suppressor cells (MDSCs) and cytokine profiles. MDSC functionality was tested in vitro. In four severe and in four mild patients, a longitudinal analysis was performed daily from the day of admission to the early convalescent phase. Early after admission severe patients showed neutrophilia, lymphopenia, increase in effector T cells, a persisting higher expression of CD95 on T cells, higher serum concentration of IL-6 and TGF-β, and a cytotoxic profile of NK and T cells compared with mild patients, suggesting a highly engaged immune response. Massive expansion of MDSCs was observed, up to 90% of total circulating mononuclear cells in patients with severe disease, and up to 25% in the patients with mild disease; the frequency decreasing with recovery. MDSCs suppressed T-cell functions, dampening excessive immune response. MDSCs decline at convalescent phase was associated to a reduction in TGF-β and to an increase of inflammatory cytokines in plasma samples. Substantial expansion of suppressor cells is seen in patients with severe COVID-19. Further studies are required to define their roles in reducing the excessive activation/inflammation, protection, influencing disease progression, potential to serve as biomarkers of disease severity, and new targets for immune and host-directed therapeutic approaches.Keywords
Funding Information
- Ministero della Salute (Ricerca Corrente Linea 1)
- EC | Horizon 2020 Framework Programme (PANDORA-ID-NET, PANDORA-ID-NET)
This publication has 31 references indexed in Scilit:
- Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancerInnate Immunity, 2012
- Myeloid-derived Suppressor Cells in Cancer PatientsJournal of Immunotherapy, 2012
- Myeloid derived suppressor cells in human diseasesInternational Immunopharmacology, 2011
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2011
- The growing diversity and spectrum of action of myeloid‐derived suppressor cellsEuropean Journal of Immunology, 2010
- Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell functionThe Journal of Experimental Medicine, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- l-arginine availability regulates T-lymphocyte cell-cycle progressionBlood, 2006
- Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing HostCancer Research, 2006
- Monocyte deactivation in septic patients: Restoration by IFN-γ treatmentNature Medicine, 1997